CLAIMS:

1. A synthetic filamentous bacteriophage simultaneously displaying interleukin-2 (IL-2) and a Programmed Death-Ligand 1 (PD-L1) targeting moiety.

2. The bacteriophage of claim 1, wherein the IL-2 is displayed on pIII, pVI, pVII, pVIII, or pIX, or a combination thereof.

3. The bacteriophage of claim 1, wherein the IL-2 is displayed on pIX.

4. The bacteriophage of claim 1, wherein the IL-2 is displayed on pIII.

5. The bacteriophage of any one of claims 1 to 4, wherein the PD-L1 targeting moiety is an antibody or an antibody mimetic.

6. The bacteriophage of claim 5, wherein the PD-L1 targeting moiety is an anti-PD-L1 scFv or a fragment thereof.

7. The bacteriophage of any one of claims 1 to 6, wherein the PD-L1 targeting moiety is displayed on pIII, pVI, pVII, pVIII, or pIX, or a combination thereof.

8. The bacteriophage of claim 7, wherein the PD-L1 targeting moiety is displayed on pIX.

9. The bacteriophage of claim 7, wherein the PD-L1 targeting moiety is displayed on pIII.

10. A pharmaceutical composition comprising the bacteriophage of any one of claims 1 to 9, together with a suitable pharmaceutical carrier.

11. Use of the bacteriophage of any one of claims 1 to 9, or the pharmaceutical composition of claim 10, for the manufacture of a medicament for treating cancer in a subject.

12. The use according to claim 11, wherein the bacteriophage or pharmaceutical composition is administered intratumorally.

13. The use according to claim 11 or 12, wherein the lung cancer, breast cancer, bladder cancer, or skin cancer.

14. The use according to any one of claims 11 to 13, wherein the bacteriophage or pharmaceutical composition is used in combination with one or more additional therapeutic agents.

15. The use according to claim 14, wherein the one or more additional therapeutic agents comprises a checkpoint inhibitor.